Showing 2451-2460 of 3223 results for "".
- Samsung Bioepis and Biogen Announce EC Approval of Eylea Biosimilar Opuvizhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ec-approval-of-eylea-biosimilar-opuviz/2482545/Samsung Bioepis and Biogen jointly announced that the European Commission (EC) has granted approval for Opuviz 40 mg/mL for injection in a vial. The biosimilar, also known as SB15, references the established treatment Eylea (aflibercept) and was developed by Samsung Bioepis. T
- Kian Capital and RF Investment Partners to Launch US VisionMed Partnershttps://modernod.com/news/kian-capital-and-rf-investment-partners-to-launch-us-visionmed-partners/2482540/Kian Capital Partners and RF Investment Partners, two private investment firms, have announced the launch of US VisionMed Partners, a management services organization (MSO). US VisionMed Partners aims to elevate optometry practices by offering a unique model focused on medically advance
- Harrow Launches Initiative to Expand Access and Affordability for Eye Care Medicationshttps://modernod.com/news/harrow-launches-initiative-to-expand-access-and-affordability-for-eyecare-medications/2482538/Harrow announced an initiative aimed at enhancing access and affordability for its ophthalmic pharmaceutical products. This program includes targeted price reductions for several widely used Harrow products, along with a strategic partnership with prescription savings platform GoodRx. <
- Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2https://modernod.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2/2482531/Neurotech Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date by 3 months to allow time required for the FDA to review additional data provided by the company in response to recent requests from the FDA. Originally set for December 17
- LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMDhttps://modernod.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd/2482525/The FDA has granted authorization to LumiThera allowing the company to market its Valeda Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to treat vision loss in patients with dry AMD.
- Johnson & Johnson Presents New Data on ACUVUE OASYS MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-presents-new-data-on-acuvue-oasys-max-1-day-contact-lenses/2482523/Johnson & Johnson will present data at Academy of Optometry 2024 on the ACUVUE OASYS MAX 1-Day family of contact lenses including contrast sensitivity, brightness of natural images, lens handling, and more. Data will also be presented on myopia management, use of digital technologie
- Genentech Announces Phase 4 Results for Vabysmo in Treating DME Among Underrepresented Populationshttps://modernod.com/news/genentech-announces-phase-4-results-for-vabysmo-in-treating-dme-among-underrepresented-populations/2482514/Genentech revealed promising 1-year findings from its phase 4 ELEVATUM study for Vabysmo (faricimab-svoa) for diabetic macular edema (DME) in racial and ethnic groups typically underrepresented in clinical trials. Results presented at the American Academy of Ophthalmology (AAO) 2024 annual m
- Stanford University Study Finds Ovarian Cancer Drug Can Affect the Eyeshttps://modernod.com/news/stanford-university-study-finds-ovarian-cancer-drug-can-affect-the-eyes/2482510/A study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago found Mirvetuximab soravtansine (Elahere) is associated with corneal toxicity and related vision changes. Mirvetuximab is part of an emerging class of anti-cancer drugs called antibody-drug conjugates. A
- Ocuphire Acquires Gene Therapy Company Opus Geneticshttps://modernod.com/news/ocuphire-acquires-gene-therapy-company-opus-genetics/2482508/Ocuphire Pharma announced an all-stock acquisition of Opus Genetics, a clinical-stage gene therapy company specializing in inherited retinal diseases (IRDs). As part of the deal, the combined company will be renamed Opus Genetics, effective October 23, 2024, and will begin trading under the
- Annexon to Present New Phase 2 Data on ANX007 for Geographic Atrophy at AAO 2024https://modernod.com/news/annexon-to-present-new-phase-2-data-on-anx007-for-geographic-atrophy-at-aao-2024/2482491/Annexon will present new analyses from the completed phase 2 ARCHER trial of ANX007 for the treatment of geographic atrophy (GA) at the American Academy of Ophthalmology (AAO) 2024 annual meeting. The company will also showcase findings at the Eyecelerator conference, held in conjunction with AAO